Phoenix WNL to handle 2x2 crossover study with multip group [Software]

posted by ElMaestro  – Denmark, 2014-06-29 01:23 (4375 d 13:11 ago) – Posting: # 13166
Views: 31,222

Hello Zan,

I don't speak WNL but:

❝ 1. is it acceptable to just assign 4 periods to the 4 dosing days? If so,

❝ In the model specification: Treatment+Sequence+Period

❝ and in the variance structure--Random effect: Subject(Sequence).


That would be a little untraditional with four period levels. But it can be done and it is a little like working with period in group. What's the title of your study? (If it is something like "A two-treatment, two-period, two-sequence bioequivalence study blah blah" then you almost have the answer right there).

❝ 2. Can we still keep these 2 periods and add a Group term to these subjects (eg. Group 1 and Group 2)?. If so, in the model specification:

❝ Treatment+Sequence+Period+Group


Yes, much better, this is what I would do.

❝ but in the variance structure, I dont know what is appropriate to be added in the Random effect field. Should it be Subject(Sequence*Group).


Oh here we go again: Depending on your data listing you can probably just write Subject.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
242 visitors (0 registered, 242 guests [including 158 identified bots]).
Forum time: 14:35 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5